A Setback In Its High-Profile “Nuc” Trial Creates An Overhang For Gilead’s HCV Pipeline
This article was originally published in The Pink Sheet Daily
Gilead concedes that 12 weeks of treatment with ribavirin and GS-7977, the high-profile “nuc” asset it obtained when it bought Pharmasset late in 2011 is suboptimal for genotype 1 null responders; general expectation is that longer duration of therapy might suffice.
You may also be interested in...
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.